Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
15 janv. 2025 09h52 HE
|
Trethera Corporation
LOS ANGELES, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
14 janv. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
13 janv. 2025 06h30 HE
|
Regeneron Pharmaceuticals, Inc.
Regeneron shares corporate progress and highlights from the Company’s broad and diverse investigational pipeline.
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
10 janv. 2025 08h00 HE
|
Barinthus Biotherapeutics
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
09 janv. 2025 10h00 HE
|
Numab Therapeutics AG
CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and...
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
07 janv. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors
11 déc. 2024 07h01 HE
|
GEn1E Lifesciences Inc.
Dr. Nader, current Independent Board Director at Moderna and Senior Advisor at Blackstone Life Sciences, joins GEn1E Lifesciences board as chair.
Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
09 déc. 2024 02h00 HE
|
Bionical Emas
Bionical Emas, the Early Access Programs and Clinical Trial Supply business, is selling EMAS Pharma to Kester Capital and an incoming executive team.
Kester Capital backs experienced management team in acquiring EMAS Pharma
09 déc. 2024 02h00 HE
|
EMAS Pharma
Kester Capital, alongside a new senior management team, has acquired EMAS Pharma, the clinical development division of Bionical Emas.
2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World
19 nov. 2024 08h00 HE
|
BioTech Breakthrough
LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...